been the hypothesis for some analysis of randomized clinical trials. Information on the impact of different ART regimens on inflammatory biomarkers linked with mortality remains, however, very limited. Recently, integrase inhibitors have shown to improve inflammation or immune activation markers when compared to non-nucleoside reverse transcriptase inhibitors. In particular, when compared to efavirenz, raltegravir normalized the CD4/CD8 ratio faster than efavirenz (Serrano-Villar et al., 2016) , and elvitegravir/cobicistat induced larger decreases of markers of monocyte activation (sCD14), systemic (hsCRP) and vascular inflammation (Lp-PLA2) (Hileman et al., 2015) . No such analysis has been performed so far with the nucleos(t)ide reverse transcriptase inhibitors (NRTIs) which are included in all the recommended regimens for treatment initiation of HIV-infection.
For this reason, the article by Funderburg et al. in this issue of EBioMedicine (Funderburg et al., 2016 ) is especially pertinent. Based on a large, double-blind clinical trial, this substudy examines changes in different biomarkers of local and systemic inflammation, comparing tenofovir alafenamide (TAF) with tenofovir disoproxil fumarate (TDF) both in combination with emtricitabine and elvitegravir/cobicistat. TAF is a new prodrug of tenofovir diphosphate that has been shown to have an efficacy similar to TDF while improving the renal and bone toxicity in clinical trials. However, information on the changes in markers of inflammation is lacking. The results show that, as expected, there were significant declines of most markers from baseline in both arms, and that TAF is as effective as TDF at reducing markers of immune activation and inflammation associated with the development of non-AIDS events and all-cause mortality.
In addition to being the first report on the impact of different NRTIs in the changes in inflammation biomarkers, the information provided in this article is relevant for several reasons. Tenofovir-based regimens are the preferred choice for most patients throughout the world, so any new information on the drug will have an impact on a large number of persons. In the near future, many patients will begin therapy with or will be switched to a TAF-based regimen, based on the good efficacy and safety profile of the drug compared to TDF. So, providing information supporting a beneficial anti-inflammatory profile is reassuring for both physicians and patients. Even if we have learnt that TAF does not outperform TDF at this regard, we can inform our patients now about the lack of any potential loss of previous benefit with TAF-based regimens, at least in the short term.
We have reached nearly optimal levels in individual antiretroviral drugs and in combination therapies. The goal of achieving durable suppression of HIV replication and long-standing undetectable viral load, with a well-tolerated, non-toxic regimen is now an accessible task for 
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EBioMedicine j o u r n a l h o m e p a g e : w w w . e b i o m e d i c i n e . c o m most physicians in the world. But persistent immune activation and inflammation despite virological control still persists, as do the associated clinical events that determine the long-term morbidity and mortality of treated patients. Information on the effect of antiretroviral drugs and regimens on these important effects are needed. Practicing physicians will certainly welcome it.
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